Nevirapine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Nevirapine |
| DrugBank ID | DB00238 |
| Brand Names (EU) | Viramune |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.91% |
Approved Indication (EMA)
Viramune 50 mg/5 mL oral suspension and 200 mg tablets Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing. Viramune 400 mg prolonged-release tablets Viramune is i
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.91% | DL |
| 2 | simian immunodeficiency virus infection | 99.85% | DL |
| 3 | feline acquired immunodeficiency syndrome | 99.85% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.82% | DL |
| 5 | AIDS | 99.38% | DL |
| 6 | fibroma of prostate | 98.99% | DL |
| 7 | Brenner tumor | 98.92% | DL |
| 8 | benign reproductive system neoplasm | 98.90% | DL |
| 9 | benign prostate phyllodes tumor | 98.77% | DL |
| 10 | male reproductive organ cancer | 98.62% | DL |
| 11 | AIDS related complex | 98.52% | DL |
| 12 | congenital human immunodeficiency virus | 98.52% | DL |
| 13 | prostate leiomyoma | 98.45% | DL |
| 14 | prostate cancer/brain cancer susceptibility | 98.40% | DL |
| 15 | obsolete familial combined hyperlipidemia | 97.66% | DL |
| 16 | breast fibrocystic disease | 97.06% | DL |
| 17 | apocrine adenosis of breast | 96.23% | DL |
| 18 | blunt duct adenosis of breast | 96.23% | DL |
| 19 | benign mammary dysplasia | 95.66% | DL |
| 20 | mycotic corneal ulcer | 94.04% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.